TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32036491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard triplet regimen comprising aprepitant, a 5-HT3 receptor antagonist, and dexamethasone 7.5 mg on days 2-4)
Study: 35567836
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose corticosteroids
Study: 33374524
Drug: Encapsulated dry
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated dry maté extract providing 580 mg of caffeoyl quinic acid derivatives (CQAs) daily
Study: 32740481
Drug: E2/P4 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/P4 (all doses)
Study: 33852195
Drug: Isocaloric glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric glucose (GLU) administration
Study: 33856589
Drug: Resective surgery
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resective surgery with the insertion of HAM patch (Group A)
Study: 35365582
Drug: tofacitinib in
Normalized name: Product containing tofacitinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib in the Oral Psoriatic Arthritis TriaL program
Study: 36116927
Drug: Recombinant poly-epitope
Normalized name: Recombinant chimeric COVID-19 epitope DC vaccine;
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant poly-epitope vaccine EgG1Y162-2 (4)
Study: 34156639
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with 50 mg/kg zinc acetate (T1)
Study: 34156639
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with 200 mg/kg zinc acetate (T2)
Study: 34156639
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with 300 mg/kg zinc acetate (T3)
Study: 34807723
Drug: Routine fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fluid administration deemed inappropriate
Study: 32459282
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (RS) supplementation (16 g/day for four weeks)
Study: 87266332
Drug: Cefuroxime (two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (two-dose peroperative regimen)
Study: 36008082
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (Methylprednisolone)
Study: 32758282
Drug: Propolis tablet
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis tablet (450 mg, containing 100 mg polyphenol compounds), twice daily for 6 weeks
Study: 32758282
Drug: Identical placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo, twice daily for 6 weeks
Study: 34487871
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional laser-assisted photodynamic therapy (AFL-PDT)
Study: 32729954
Drug: Acellular dermal
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular dermal matrix (ADM) treatment
Study: 34688699
Drug: Teprotumumab treatment
Normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teprotumumab treatment (8 infusions over 24 weeks)
Study: 34688699
Drug: Teprotumumab re-treatment
Normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teprotumumab re-treatment
Study: 34688699
Drug: Teprotumumab treatment
Normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teprotumumab treatment
Study: 34587702
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy alone
Study: 34277982
Drug: Hypoglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemic clamp (2.2-2.5 mmol/L)
Study: 34277982
Drug: Euglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemic clamp (4.5-5.5 mmol/L)
Study: 32410519
Drug: Suction and
Normalized name: TUBING,SUCTION AND FILTER KIT DEVILBISS #18600-KITN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suction and local steroid injection (Group B)
Study: 33216167
Drug: Nicotine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7 mg/24 h, transdermally)
Study: 33216167
Drug: Mecamylamine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (7.5 mg, p.o.)
Study: 34902004
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - fluticasone propionate, 50 μg, with placebo, 2 puffs twice daily for 12 weeks
Study: 34902004
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) - fluticasone propionate, 50 μg, with salmeterol, 25 μg, 2 puffs twice daily for 12 weeks
Study: 32361959
Drug: Underwater weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underwater weight bath traction therapy and NSAIDs
Study: 33638928
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Er: YAG laser and autologous platelet-rich plasma (PRP)
Study: 33297866
Drug: Alteplase at
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase at 0.6 mg/kg intravenously
Study: 32317109
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release therapy (5 sessions over 2 weeks)
Study: 32317109
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy program (10 sessions of massage, ultrasound therapy, and transcutaneous electric nerve stimulation over 2 weeks)
Study: 37853420
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release therapy
Study: 32321955
Drug: Control teeth
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control teeth (no treatment)
Study: 34529811
Drug: Caffeinated gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated gum (4 mg/kg)
Study: 35255814
Drug: Near point-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near point-of-care CT and NG testing and treatment intervention
Study: 32658797
Drug: Dexmedetomidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine plus ropivacaine (1 μg kg−1 dexmedetomidine and 0.25% ropivacaine)
Study: 33451627
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1000 mg)
Study: 32046665
Drug: Upfront combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront combination therapy
Study: 35235834
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention with just-in-time adaptive intervention (JITAI) promoting low-level physical activity and exercise, including access to activity tracking and goal setting through a mobile application, and weekly activity summaries via email.
Study: 34729682
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (0.6 mg)
Study: 33608239
Drug: FDA-approved new
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved new generation drug-eluting stent followed by guideline-recommended DAPT duration (3 or 6 months)
Study: 34034268
Drug: Midodrine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (15 mg daily) and albumin (20 g weekly) in group‐A (Gp‐A)
Study: 34034268
Drug: Albumin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (20 g weekly) alone in group‐B (Gp‐B)
Study: 33872448
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral antibiotics with mechanical bowel preparation (MBP)
Study: 33872448
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral antibiotics without mechanical bowel preparation (control)
Study: 33872448
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral antibiotics with MBP
Study: 33872448
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral antibiotics without MBP (control)
Study: 33057642
Drug: Prehospital plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital plasma administration (2 units of thawed plasma)
Study: 33057642
Drug: Prehospital plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital plasma administration
Study: 33352600
Drug: Marine phytoplankton
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine phytoplankton 2.55 mg·d‐1
Study: 33352600
Drug: Marine phytoplankton
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine phytoplankton 5.1 mg·d‐1
Study: 34744149
Drug: Ivabradine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (20 mg)
Study: 34744149
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (20 mg)
Study: 38587333
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid
Study: 35460392
Drug: AMG 986
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 986 (up to 650 mg/day)
Study: 33653320
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + Serratiopeptidase
Study: 33653320
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Paracetamol
Study: 36088057
Drug: Prolutex (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolutex (25 mg daily)
Study: 36088057
Drug: Crinone (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone (90 mg daily)
Study: 32062671
Drug: Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab combination therapy
Study: 32062671
Drug: Cetuximab as
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab as an alternative treatment
Study: 32062671
Drug: Cetuximab treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment for ≥10 months
Study: 33990437
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (placebo group)
Study: 35871718
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa (NS) oil supplementation (2 g/daily for 8 weeks)
Study: 32197620
Drug: CHF6001 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 800 μg BID
Study: 32197620
Drug: CHF6001 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 1600 μg BID
Study: 32561266
Drug: HTX-011 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 400 mg bupivacaine/12 mg meloxicam
Study: 32561266
Drug: HTX-011 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 400 mg bupivacaine/12 mg meloxicam with 50 mg ropivacaine
Study: 32561266
Drug: Bupivacaine hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine hydrochloride (HCl) 125 mg injection
Study: 32889881
Drug: Novel Oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel Oral Anticoagulant (NOAC) therapy
Study: 33285008
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma (15 ml.kg−1)
Study: 32527676
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality based cognitive behavioral therapy (VR‐CBT)
Study: 33839552
Drug: Aromatherapy (inhalation)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy (inhalation)
Study: 35253448
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (450 mg/d)
Study: 35253448
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (450 mg/d)
Study: 35253448
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (450 mg/d)
Study: 35218628
Drug: Pinggan Jiangya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinggan Jiangya decoction combined with penetrating needling at Baihui (GV20) once daily for 8 weeks
Study: 35218628
Drug: Pinggan Jiangya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinggan Jiangya decoction once daily for 8 weeks
Study: 33418362
Drug: CADSS-6 (6-item
Approvals — FDA: no, EMA: no, PMDA: no
Description: CADSS-6 (6-item version of the Clinician-Administered Dissociative States Scale)
Study: 33415915
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) as add-on treatment
Study: 33751652
Drug: Personal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal oral hygiene (pOH) at daily intervals (12-24 hours)
Study: 33751652
Drug: Personal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal oral hygiene (pOH) at extended intervals (48 hours)
Study: 33474858
Drug: Aspirin desensitization
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin desensitization
Study: 34506358
Drug: Daily mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mobile reporting
Study: 34506358
Drug: Daily swabbing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily swabbing arm
Study: 33212256
Drug: Favipiravir (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir (1800 mg BID on day 1 and 800 mg BID from days 2-14) plus standard supportive care
Study: 36462528
Drug: Single low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single low-dose primaquine combined with artemether-lumefantrine
Study: 36462528
Drug: Single low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single low-dose primaquine combined with dihydroartemisinin-piperaquine
Study: 32037149
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin 200 mg/kg/day for 8 weeks
Study: 33060432
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) ketamine 0.5 mg/kg
Study: 33060432
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 1 mg/kg
Study: 36271428
Drug: Multimodal chiropractic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal chiropractic care including spinal manipulation, education, exercise, self-management advice, and myofascial therapies over 8 weeks, twice weekly sessions
Study: 33615628
Drug: TAS0313 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS0313 (9 mg)
Study: 33615628
Drug: TAS0313 (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS0313 (27 mg)
Study: 33615628
Drug: TAS0313 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS0313 (9 mg and 27 mg)
Study: 35120861
Drug: Tactile, kinesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tactile, kinesthetic and oral stimulation (T + K + OS)
Study: 34024541
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three CT slices (L2, L3, L4)
Study: 33397432
Drug: PVP-I nasal
Normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PVP-I nasal spray at 0.5%
Study: 33397432
Drug: PVP-I nasal
Normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PVP-I nasal spray at 0.6%
Study: 33397432
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water through nasal spray (placebo)
Study: 35830988
Drug: Low-dose low-molecular-weight-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose low-molecular-weight-heparin (LMWH) therapy
Study: 35830988
Drug: High-dose low-molecular-weight-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose low-molecular-weight-heparin (LMWH) therapy
Study: 35830988
Drug: High-dose low-molecular-weight-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose low-molecular-weight-heparin (LMWH) with aspirin
Study: 35503305
Drug: SBIRT Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SBIRT Intervention for Trauma Patients (SITP) - a 15-minute session with elements of cognitive behavioral therapy techniques
Study: 35748760
Drug: The Daily
Normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Daily Mile (TDM) - a daily one mile outdoor run/walk performed at a self‐selected pace during school hours
Study: 35748760
Drug: The Daily
Normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Daily Mile (TDM)
Study: 35546449
Drug: HDV-insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HDV-insulin lispro with a 10% decrease in BaI dose
Study: 35546449
Drug: HDV-insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HDV-insulin lispro with a 40% decrease in BaI dose
Study: 33048394
Drug: Screening attendance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening attendance (at least twice)
Study: 34715000
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable antipsychotics (LAI)
Study: 34715000
Drug: Oral atypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atypical antipsychotics (OAA)
Study: 33786649
Drug: Azithromycin (AZI)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZI) 500 mg/day for 3 days
Study: 34330456
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (2000 mg/d)
Study: 34118498
Drug: IVY intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVY intervention (vaccine education and quality improvement program)
Study: 34407695
Drug: Sachet water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sachet water (46% consumption); bottled water (100%, n=2); chlorine-based disinfectants for water treatment
Study: 33559648
Drug: Skin prick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin prick testing and measurement of volatile organic compounds in exhaled breath
Study: 32147075
Drug: Curcuminoids (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (500 mg plus 5 mg piperine per day for 8 weeks)
Study: 32436902
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids 500 mg (EPA/DHA 180/120 mg), BD daily for 1 month
Study: 32325043
Drug: NOACs (nonvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOACs (nonvitamin K antagonist oral anticoagulants)
Study: 35447066
Drug: Met52 fungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Met52 fungal spray
Study: 36253611
Drug: Anti-tau monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-tau monoclonal antibody gosuranemab
Study: 34454786
Drug: Ro‐VLP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro‐VLP vaccine (21 μg) in adults
Study: 34454786
Drug: Ro‐VLP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro‐VLP vaccine (7 μg or 21 μg) in toddlers
Study: 34454786
Drug: Ro‐VLP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro‐VLP vaccine (2.5 μg, 7 μg or 21 μg) in infants
Study: 34454786
Drug: Oral Rotarix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Rotarix (2 doses) in infants
Study: 36572280
Drug: Total neoadjuvant
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total neoadjuvant therapy (TNT)
Study: 32270474
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL ropivacaine 0.2% bilaterally and an elastomeric pump containing 0.2% ropivacaine
Study: 32270474
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL saline bilaterally and an elastomeric pump containing saline
Study: 33008432
Drug: Motor Imagery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor Imagery practice combined with routine physical therapy (MIp)
Study: 33008432
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving physical therapy alone (CON)
Study: 35351144
Drug: Inulin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (16 g/day) with dietary advice for 3 months
Study: 33924761
Drug: W. cibaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: W. cibaria CMU tablets administered once daily for 8 weeks before bedtime
Study: 33924761
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily for 8 weeks before bedtime
Study: 32665367
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (Palforzia)
Study: 34119410
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping with voice therapy